SAREPTA THERAPEUTICS, INC. Payments to Acquire Available-for-sale Securities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments to Acquire Available-for-sale Securities of $651.39 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-10-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-10-31
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $355.56M.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $204.31M.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $91.51M.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $489.17M.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $589.52M, a 201.66% increase from fiscal 2016.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $195.43M, a 20.63% increase from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $162.00M, a 40.95% decline from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2014 was $274.37M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 404 month |
|---|---|---|---|---|---|
| 2018-09-30 | $355.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $559.87M derived: sum of 2 quarters · filed 2018-10-31 | $651.39M 10-Q · filed 2018-10-31 | $1.14B derived: sum of 4 quarters · filed 2018-10-31 | |
| 2018-06-30 | $204.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $295.82M 10-Q · filed 2018-08-08 | $785.00M derived: sum of 3 quarters · filed 2018-08-08 | $785.00M derived: sum of 4 quarters · filed 2018-10-31 | |
| 2018-03-31 | $91.51M 10-Q · filed 2018-05-03 | $580.69M derived: sum of 2 quarters · filed 2018-05-03 | $580.69M derived: sum of 3 quarters · filed 2018-10-31 | ||
| 2017-12-31 | $489.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $489.17M derived: sum of 2 quarters · filed 2018-10-31 | $589.52M 10-K · filed 2018-03-01 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $100.35M 10-Q · filed 2018-10-31 | |||
| 2017-06-30 | $100.35M 10-Q · filed 2018-08-08 | ||||
| 2016-12-31 | $195.43M 10-K · filed 2018-03-01 | ||||
| 2015-12-31 | $112.37M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $112.37M derived: sum of 2 quarters · filed 2018-03-01 | $162.00M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $49.63M 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | $49.63M 10-Q · filed 2016-08-09 | ||||
| 2014-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $47.75M derived: sum of 2 quarters · filed 2017-02-28 | $97.70M derived: sum of 3 quarters · filed 2017-02-28 | $274.37M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $45.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $95.52M derived: sum of 2 quarters · filed 2015-11-05 | $272.19M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $49.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $226.62M 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $176.67M 10-Q · filed 2015-05-07 | $289.66M 10-Q · filed 2014-05-08 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |